Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness
June 09 2022 - 9:00AM
Business Wire
Industry Leader Plans
Largest Recognized Medical Outreach to Provide Hope to
Vast Numbers of Those Afflicted or Hoping to
Avoid Tick-Borne Affliction
With Lyme disease season in full-swing across the United States
and as the public continues spending increasing time outdoors
during the COVID-19 pandemic, Quidel’s recently formed Lyme Task
Force Team—the only one of its kind—today announced a multitiered
collaboration with Global Lyme Alliance to dramatically heighten
public awareness to a health condition afflicting nearly half a
million Americans each year.
Quidel is the nation’s leading developer of the only rapid
point-of-care diagnostic Lyme disease test. In recent years the
company launched the critically acclaimed and award-winning
LymeDiseaseAnswers.com website and Lyme Quick Takes online video
series.
“The Global Lyme Alliance has been a passionate and important
partner for Quidel in our fight against Lyme disease,” said Judi
Tilghman, Ph.D., vice president of technology assessment at Quidel.
“Over the years they have helped fund the most urgent and promising
research in the field while expanding education and awareness
programs for the public and physicians. We’re honored to have this
collaborative partnership.”
As part of its collaboration, Quidel will serve as sponsor for
GLA’s Lyme awareness month as well as a series of educational
PACE-accredited webinars. These events provide new information on
various Lyme topics in an open discussion format, all designed to
bring awareness around the Lyme disease epidemic, with rapid ways
to diagnose and treat it. In addition, Quidel will be a sponsor for
the GLA Global Gala 2022, the organization’s premier fundraising
event to be held in October.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading
manufacturer of diagnostic solutions at the point of care,
delivering a continuum of rapid testing technologies that further
improve the quality of health care throughout the globe. An
innovator for over 40 years in the medical device industry, Quidel
pioneered the first FDA-cleared point-of-care test for influenza in
1999 and was the first to market a rapid SARS-CoV-2 antigen test in
the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage®
and QuickVue®, Quidel’ s comprehensive product portfolio includes
tests for a wide range of infectious diseases, cardiac and
autoimmune biomarkers, as well as a host of products to detect
COVID-19. With products made in America, Quidel’ s mission is to
provide patients with immediate and frequent access to highly
accurate, affordable testing for the good of our families, our
communities, and the world. For more information about Quidel,
visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220609005351/en/
Jim Yeager breakwhitelight (for Quidel Corporation)
jim@breakwhitelight.com Mobile: 818-264-6812
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024